News · 26 weeks76-31%
2025-12-142026-06-07
Mix3790d
- Insider17(46%)
- SEC Filings12(32%)
- Other5(14%)
- Offering3(8%)
Latest news
25 items- SECSEC Form S-8 filed by Clene Inc.S-8 - Clene Inc. (0001822791) (Filer)
- SECSEC Form SD filed by Clene Inc.SD - Clene Inc. (0001822791) (Filer)
- SECClene Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Clene Inc. (0001822791) (Filer)
- INSIDERSEC Form 4 filed by Director Mclaughlin Vallerie4 - Clene Inc. (0001822791) (Issuer)
- INSIDERSEC Form 4 filed by Director Desai Arjun Jj4 - Clene Inc. (0001822791) (Issuer)
- INSIDERSEC Form 4 filed by Director Mosca Alison4 - Clene Inc. (0001822791) (Issuer)
- INSIDERSEC Form 4 filed by Director Matlin David J4 - Clene Inc. (0001822791) (Issuer)
- INSIDERSEC Form 4 filed by Director Jacobovitz Shalom4 - Clene Inc. (0001822791) (Issuer)
- INSIDERSEC Form 4 filed by Director Kiernan Matthew4 - Clene Inc. (0001822791) (Issuer)
- INSIDERSEC Form 4 filed by Director Gay Jonathon4 - Clene Inc. (0001822791) (Issuer)
- INSIDERSEC Form 4 filed by Director Wilcox Reed N4 - Clene Inc. (0001822791) (Issuer)
- SECClene Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Clene Inc. (0001822791) (Filer)
- PRClene Reports First Quarter 2026 Financial Results and Recent Operating HighlightsAfter successful completion of FDA Type C meeting, Clene expects to submit an NDA for CNM-Au8® under the accelerated approval pathway in the third quarter of 2026In January 2026, Clene completed an oversubscribed registered direct offering totaling over $28 million, including an initial tranche of more than $6 million and two additional tranches totaling over $22 million tied to regulatory milestones In May 2026, Clene amended its existing $10 million convertible debt facility, extending maturity by six months to August 2027 and eliminating required monthly principal and interest payments before maturityIn May 2026, Clene completed a $7 million underwritten registered direct offering with a
- SECSEC Form 10-Q filed by Clene Inc.10-Q - Clene Inc. (0001822791) (Filer)
- INSIDERLarge owner Ugwumba Chidozie sold $604,130 worth of shares (95,473 units at $6.33) (SEC Form 4)4 - Clene Inc. (0001822791) (Issuer)
- PRPresenting on Emerging Growth Conference 92 Day 2 on May 7; Register to live streamMIAMI, May 06, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 92nd Emerging Growth Conference on May 6 & 7, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter. Presenting today – Wednesday, May 6, 2026 9:00Virtual Lobby opens.Register for the Conference. If you already registered, go
- INSIDERLarge owner Ugwumba Chidozie sold $530,439 worth of shares (78,679 units at $6.74) (SEC Form 4)4 - Clene Inc. (0001822791) (Issuer)
- SECClene Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - Clene Inc. (0001822791) (Filer)
- SECSEC Form 424B5 filed by Clene Inc.424B5 - Clene Inc. (0001822791) (Filer)
- SECSEC Form 424B5 filed by Clene Inc.424B5 - Clene Inc. (0001822791) (Filer)
- PRClene Announces $7 Million Underwritten Offering of Common StockSALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene" or the "Company") and its wholly owned subsidiary, Clene Nanomedicine, Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced the pricing of an underwritten registered direct offering of 1,000,000 shares of common stock at a purchase price of $7.00 per share to a single investor. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are
- PRClene to Present at Upcoming May ConferencesSALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that it will participate in the following investor conferences in May. Emerging Growth ConferenceDate: May 6, 2026Time of Presentation: 3:25 p.m. ETFormat: Virtual PresentationPresentation Link: https://goto.webcasts.com/starthere.jsp?ei=1755070&tp_key=280dc3ffe3&sti=clnn D. Boral Capital Global Conference Date: M
- PRPresenting on Emerging Growth Conference 92 Day 1 on May 6; Register to live streamMIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 91st Emerging Growth Conference on May 6 & 7, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 1 - WednesdayMay 6, 2026 9:00Virtual Lobby opens.Register for the Conference. If you already registered, go back to the re
- SECClene Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Clene Inc. (0001822791) (Filer)
- PRAfter Successful FDA Meeting, Clene Filing Accelerated Approval NDA for ALSFDA stated that the "proposed data may be capable of supporting the submission and review of an [NDA] under the accelerated approval pathway" for CNM-Au8 based on neurofilament light (NfL) biomarker dataFDA acknowledged NfL could potentially serve as a reasonably likely surrogate endpointClene expects to submit an NDA for CNM-Au8 to the FDA in the third quarter of 2026CNM-Au8 represents a potential first-in-class therapeutic approach for ALS, a disease area with significant unmet medical need SALT LAKE CITY, May 04, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopha
CLNN FAQ
6 questionsWhat does Clene Inc. do?
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean surfaced nanotechnology (CSN) therapeutics. The company has a nanotechnology drug suspension; and engages in the development and commercialization of dietary supplements. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2 study for the treatment of stable multiple sclerosis; a Phase 2 biomarker study in Parkinson's; and Phase 2 and Phase 3 trials to investigate the potential for disease modification for neurodegenerative...Where does CLNN stock trade?
Clene Inc. (CLNN) is listed on NASDAQ.What sector and industry is CLNN in?
Clene Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about CLNN?
Clene Inc. has had 4 recent analyst actions on file. The most recent action was from Oppenheimer: Perform on 2022-10-04. Recent price targets range from $1000.00 to $2000.00.What companies are similar to CLNN?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare CLNN side-by-side with any of them on Quantisnow.How can I track CLNN on Quantisnow?
Quantisnow aggregates Clene Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CLNN to receive live email and push alerts on every new disclosure.